Latest News
Pfizer Starna Deal: What Does Pfizer Get for $330 Million Upfront?
The Pfizer Starna deal gives Pfizer three early in vivo CAR-T programmes for autoimmune diseases, for $330 million upfront. Pfizer announced the exclusive licensing agreement with Starna Therapeutics on 18 November 2026. Starna is eligible for up to $2.3 billion in...
Latest News
Risto-cel Approval: When Could Beam’s Sickle Cell Therapy Reach Patients?
Beam Therapeutics plans to file for US risto-cel approval as early as year-end 2026. Under the FDA’s published review goals, a decision would follow roughly eight to 12 months after submission. No FDA action date has been announced. The plan follows positive topline...
argenx Unnatural Products Deal: What Does $550 Million Upfront Buy?
The argenx Unnatural Products deal buys a macrocyclic peptide discovery platform and its Santa Cruz research team. It also brings a portfolio of therapeutic macrocycles, none of which the companies have named. argenx will pay $550 million upfront in cash. Up to $595...
Beyond the Magic Marker: What EEG Could Add to ADHD Assessment
The search for a single brainwave test for ADHD has largely failed. But that was always the wrong goal. The more useful question is whether EEG, used alongside clinical assessment, could add information that helps make ADHD assessment more accurate and treatment more...
From GLP-1 Trial Results to the Follow-Up Visit
A patient returns for follow-up after starting a GLP-1 receptor agonist. Their weight is down, but nausea has made meals unpredictable, and their insurer has declined the next refill. The GLP-1 trial results that helped start the conversation are still relevant. The...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
GLP-1s in Adolescents: What the Paediatric Obesity Evidence Shows
The case for GLP-1s in adolescents with obesity now rests on several randomised trials and two marketing authorisations. Real-world data are growing too. That evidence shows substantial reductions in body mass index over 56 to 68 weeks. It says much less about years...
Eppendorf and BioLabs Expand Collaboration to Munich
The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...
Divarasib Approval: When Could Roche’s KRAS Inhibitor Reach Patients?
Divarasib approval has no confirmed date, but Roche’s own guidance points to 2027. Roche’s Pharma Day slides of 28 September 2026 list US and EU approval as a 2027 milestone. No regulatory filing for the KRAS G12C inhibitor had been announced in the sources reviewed...
Beyond Screen Time: How Digital Habits Shape Attention and Memory
As digital platforms make information increasingly accessible, the challenge is no longer simply how much we consume, but how our digital habits affect the way we process, retain, and use it. Scrolling through social media can expose us to hundreds of pieces of...
ZW209 Licensing Deal: What Does Roche Get From Zymeworks?
Under the ZW209 licensing deal with Zymeworks, Roche will receive exclusive global rights to develop and commercialise ZW209. In return, Zymeworks is due $55 million upfront and $40 million when a Phase 1b trial begins. It is also eligible for up to $718 million in...
What FDA’s “Healthy” Rule and Front-of-Pack Labelling Mean for Food Makers
Two changes are reshaping what goes on the front of a US food package. The first, a new definition of the "healthy" nutrient content claim, is already law, with enforcement starting on 25 February 2028 [1]. The second, mandatory front-of-pack labelling in the form of...
Life Science Publishing: Our First Year, and Where You Fit In
Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
Imdelltra Imfinzi Approval: When Could First-Line Use Begin?
Amgen and AstraZeneca presented full DeLLphi-305 results at the ESMO Congress in Madrid. The phase 3 trial added Amgen’s Imdelltra (tarlatamab-dlle) to AstraZeneca’s Imfinzi (durvalumab). It cut the risk of death by 58 per cent in extensive-stage small cell lung...
OOS Investigation: A Solubility-Related HPLC Assay Failure
A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...
Pharma’s Digital Maturity Divide Is Holding Back AI Adoption
AI is creating new opportunities across the pharmaceutical industry, but not every organisation is equally equipped to capitalise on them. The differentiator is not simply access to AI, but digital maturity; the strength of the infrastructure underpinning it. Those...
UK Biotech Venture Capital Nears a Record Year as Seed Funding Shrinks
UK biotech venture capital reached £2.84 billion in the first nine months of 2026. That is more than in any full year from 2022 to 2025. The figures come from the BioIndustry Association (BIA) Q3 2026 financing report, published on 26 October 2026 [1]. The BIA puts...
Connecting ADME and Mouse Models in Preclinical Oncology
In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...
GLP-1s in Adolescents: What the Paediatric Obesity Evidence Shows
The case for GLP-1s in adolescents with obesity now rests on several randomised trials and two marketing authorisations. Real-world data are growing too. That evidence shows substantial reductions in body mass index over 56 to 68 weeks. It says much less about years...
Eppendorf and BioLabs Expand Collaboration to Munich
The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...
Divarasib Approval: When Could Roche’s KRAS Inhibitor Reach Patients?
Divarasib approval has no confirmed date, but Roche’s own guidance points to 2027. Roche’s Pharma Day slides of 28 September 2026 list US and EU approval as a 2027 milestone. No regulatory filing for the KRAS G12C inhibitor had been announced in the sources reviewed...
Beyond Screen Time: How Digital Habits Shape Attention and Memory
As digital platforms make information increasingly accessible, the challenge is no longer simply how much we consume, but how our digital habits affect the way we process, retain, and use it. Scrolling through social media can expose us to hundreds of pieces of...
ZW209 Licensing Deal: What Does Roche Get From Zymeworks?
Under the ZW209 licensing deal with Zymeworks, Roche will receive exclusive global rights to develop and commercialise ZW209. In return, Zymeworks is due $55 million upfront and $40 million when a Phase 1b trial begins. It is also eligible for up to $718 million in...
What FDA’s “Healthy” Rule and Front-of-Pack Labelling Mean for Food Makers
Two changes are reshaping what goes on the front of a US food package. The first, a new definition of the "healthy" nutrient content claim, is already law, with enforcement starting on 25 February 2028 [1]. The second, mandatory front-of-pack labelling in the form of...
Life Science Publishing: Our First Year, and Where You Fit In
Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
Imdelltra Imfinzi Approval: When Could First-Line Use Begin?
Amgen and AstraZeneca presented full DeLLphi-305 results at the ESMO Congress in Madrid. The phase 3 trial added Amgen’s Imdelltra (tarlatamab-dlle) to AstraZeneca’s Imfinzi (durvalumab). It cut the risk of death by 58 per cent in extensive-stage small cell lung...
OOS Investigation: A Solubility-Related HPLC Assay Failure
A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...
Pharma’s Digital Maturity Divide Is Holding Back AI Adoption
AI is creating new opportunities across the pharmaceutical industry, but not every organisation is equally equipped to capitalise on them. The differentiator is not simply access to AI, but digital maturity; the strength of the infrastructure underpinning it. Those...
UK Biotech Venture Capital Nears a Record Year as Seed Funding Shrinks
UK biotech venture capital reached £2.84 billion in the first nine months of 2026. That is more than in any full year from 2022 to 2025. The figures come from the BioIndustry Association (BIA) Q3 2026 financing report, published on 26 October 2026 [1]. The BIA puts...
Connecting ADME and Mouse Models in Preclinical Oncology
In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...
Featured Articles
Further News
Weekly News Roundup | 26 October 2026
Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...
Melanoma Vaccine Approval: When Could Intismeran Reach Patients?
Melanoma vaccine approval has not happened yet. No regulator has approved intismeran autogene, and its developers have not announced a filing date. On 22 October 2026, Merck and Moderna released detailed phase 3 data. They said they are engaging with regulatory...
Exosomes Move Toward the Mainstream. Manufacturing May Be the Key to Scale
For much of the past decade, exosomes have occupied a familiar place in biotechnology: scientifically intriguing, biologically versatile and full of potential, but still some distance from becoming routinely manufactured products. That is beginning to change as...
From Regulation to Adoption: What Europe Needs Next for AI in Health
The UK and EU have reached a pivotal point in the regulation of AI in health. Both have set ambitious goals for protecting patients while enabling innovation, but success will depend on whether regulatory frameworks can be translated into responsible adoption and...
Clinical Trial Results 23 October 2026
The clinical trial results 23 October 2026 cover non-infectious uveitis, hidradenitis suppurativa, IgA nephropathy, wet AMD and metastatic colorectal cancer. Priovant’s brepocitinib met its primary endpoint in two Phase 3 trials in non-infectious uveitis. AbbVie’s...
Fenebrutinib Approval: When Could the FDA Decide on Roche’s MS Drug?
Fenebrutinib approval is now under US priority review, but Roche has not said when the FDA will decide. The company announced on 30 September 2026 that the agency had accepted its new drug application. The filing covers relapsing multiple sclerosis (RMS) and primary...
Why US Federal Legislation Is the Best Chance to Rein In PBMs
Federal legislation is the best opportunity to compel pharmacy benefit managers (PBMs) to change. Neither a major Federal Trade Commission (FTC) settlement nor reforms at the state level have fixed market distortions. But the upcoming US midterm elections in November...
The Evidence Problem in Cosmetic Actives: Why In-Vitro Data Is Not Enough
As Head of R&D at a Swiss cosmetics laboratory, I read a lot of the evidence behind the cosmetic actives that brands ask us to put in their formulas. The same pattern keeps turning up. A well-cited in-vitro mechanism gets marketed as if it were a proven clinical...
Who Owns Ilofotase Alfa Now? Inside Ambrose’s AM-Pharma Deal
Ilofotase alfa now belongs to Ambrose Healthcare, a UK-headquartered rare disease company. On 20 October 2026, Ambrose said it had acquired 100 per cent of the shares of AM-Pharma. The Dutch company, based in Utrecht, developed the drug. The deal is complete rather...
RNA-LNP Development: Creative Biolabs Links Design, Formulation & Analysis
RNA delivery research is moving beyond conventional lipid nanoparticle (LNP) formulation toward a more systematic understanding of how lipid chemistry, particle organization, and intracellular trafficking influence delivery performance. As researchers confront...
Bepirovirsen NHS Access: Will UK Hepatitis B Patients Get Hibsago?
Bepirovirsen NHS access is undecided, because the drug has no UK marketing authorisation. GSK said the US FDA approved bepirovirsen, branded Hibsago, for chronic hepatitis B on 20 October 2026. NHS patients cannot expect routine access until the MHRA authorises it and...
Pediatric Eye Injuries: Severity, Referral and Permanent Vision Loss
A child's vision is one of their most important developmental assets. Sight shapes how children learn, play, read, and connect with the world around them, and unlike many other aspects of health, vision loss caused by pediatric eye injuries can have consequences that...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.













